CN1923170A - Imiquimod turbid liquor and gelling agent thereof - Google Patents
Imiquimod turbid liquor and gelling agent thereof Download PDFInfo
- Publication number
- CN1923170A CN1923170A CN 200610140786 CN200610140786A CN1923170A CN 1923170 A CN1923170 A CN 1923170A CN 200610140786 CN200610140786 CN 200610140786 CN 200610140786 A CN200610140786 A CN 200610140786A CN 1923170 A CN1923170 A CN 1923170A
- Authority
- CN
- China
- Prior art keywords
- imiquimod
- boric acid
- gel
- turbid liquor
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002751 imiquimod Drugs 0.000 title claims description 72
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 title claims description 72
- 239000003349 gelling agent Substances 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 239000000725 suspension Substances 0.000 claims abstract description 7
- 239000000499 gel Substances 0.000 claims description 27
- 239000004327 boric acid Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 13
- 229960004756 ethanol Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 238000013019 agitation Methods 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 15
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- IDQGRVRLINQKBK-UHFFFAOYSA-N 3-chloro-1-imidazol-1-yl-4-phenylisoquinoline Chemical compound C=12C=CC=CC2=C(C=2C=CC=CC=2)C(Cl)=NC=1N1C=CN=C1 IDQGRVRLINQKBK-UHFFFAOYSA-N 0.000 abstract 3
- 229950003544 climiqualine Drugs 0.000 abstract 3
- 229960002645 boric acid Drugs 0.000 abstract 1
- 235000010338 boric acid Nutrition 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 206010059313 Anogenital warts Diseases 0.000 description 10
- 208000019802 Sexually transmitted disease Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000009608 Papillomavirus Infections Diseases 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000021145 human papilloma virus infection Diseases 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- -1 and simultaneously Substances 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a climiqualine suspension and relative production, and relative medicine, as climiqualine gel. Wherein, it uses the mixture solvent of glycerin, alcohol and boracic acid solutions, to obtain stable and uniform climiqualine suspension, to make gel agent, etc.
Description
Technical field
The present invention relates to a kind of Imiquimod turbid liquor and preparation method thereof, and the pharmaceutical preparation that comprises Imiquimod turbid liquor, especially imiquimod gel and preparation method thereof.Belong to field of medicaments.
Background technology
Condyloma acuminatum is a kind of sexually transmitted disease (STD), and it is that sickness rate is the second son gonorrhea only by due to the human papilloma virus infection, for occupying the 2nd sexually transmitted disease (STD).Treatment to condyloma acuminatum at present still lacks effective medicine.The Therapeutic Method that can adopt has caused very big misery to patient clinically, and relapse rate is high.
Imiquimod is a kind of immunomodulator, belong to the different cyclammonium class of non-nucleoside medicine, be 1997 by the immunoregulation medicament of the 1st external curing external genitalia wart of FDA (Food and Drug Adminstration) (FDA) approval, adapt to and be used for external genitalia and the crissum condyloma acuminatum that human papilloma virus infection causes, be widely used in clinical.Imiquimod has become the choice drug of treatment condyloma acuminatum in world many countries.The recommended drug of genital wart all classified this medicine as by the Center for Disease Control (CDC), European Center for Disease Control (CDC) (CDC) and " Chinese sexually transmitted disease (STD) treatment guide ".
The pharmaceutical preparation of imiquimod has 5% imiquimod cream at present, is used for the treatment of by human papilloma virus infection the most common caused sexually transmitted disease (STD)-genital wart to have better curative effect.This medicine is the micromolecule immunomodulator, but the immunoreation of irritation cell mediation induce cytokine and act on, obviously reduce HPV2 DNA (deoxyribonucleic acid) (DNA) level of skin histology.The imiquimod clinical practice has the cure rate height, relapse rate is low, side effect is little, patient can oneself operate characteristics such as administration, and the good clinical application prospect is arranged.
In the development test of imiquimod treatment condyloma acuminatum multi-center randomized double, adopt at random, the clinical research methods of double blinding, parallel control, observe the clinical efficacy and the safety of 5% imiquimod cream treatment crissum and external genitalia condyloma acuminatum.The experimenter puts the research medicine on the skin outside 3 parts weekly, cleans 8 weeks of the course of treatment with clear water in 6-8 hour after the medication.The wart body person of fully not disappearing continues to follow up a case by regular visits to 1 month to observe relapse rate.In 231 routine crissum and external genitalia condyloma acuminatum patient, 116 examples are organized in 5% imiquimod cream treatment, placebo group 115 examples.The cure rate in treatment 2,4,6,8 weeks of back is respectively 8.41%, 30.84%, 49.53% and 61.68% in the treatment group, and matched group is respectively 2.68%, 7.14%, 16.07% and 24.11%, two group difference statistical significance (P＜0.001); The effective percentage for the treatment of 2,4,6,8 weeks of back is respectively 34.58%, 60.75%, 68.22% and 74.77% in the treatment group, and matched group is respectively 10.72%, 18.75%, 28.57% and 32.14%, two group difference statistical significance (P＜0.001).The relapse rate that treatment group recovery from illness patient followed up a case by regular visits to after 1 month is 10.61%, compares the difference not statistically significant with matched group.The untoward reaction of the no system of treatment group only has the local untoward reaction of medicine-feeding part, and for seeing, incidence rate is 34.55% more with slight and moderate erythema.5% imiquimod cream treatment crissum and external genitalia condyloma acuminatum determined curative effect are described, safety is good, has toleration preferably, and is easy to use.
Imiquimod cream has definite curative effect, but because ointment has greasy feeling, easy cleaning not, and easy pollution clothes, thus influence the compliance or the compliance of patient's medication to a certain extent.Therefore, the imiquimod pharmaceutical preparation of development and development of new, significant.
Summary of the invention
The object of the invention is to provide a kind of novel imiquimod pharmaceutical preparation and preparation method thereof, with the compliance that makes things convenient for clinical application and improve the patient.Be the detailed technical scheme of the present invention below.
As one of the object of the invention, a kind of Imiquimod turbid liquor is provided, comprise imiquimod and solvent, it is characterized in that the mixed solvent of described solvent for forming by glycerol, ethanol, boric acid and water.
Wherein, in the above-mentioned described mixed solvent, the proportioning of glycerol, ethanol, boric acid and water can be determined by suitable test according to the invention needs.Among the present invention, described Imiquimod turbid liquor in the wherein said solvent, is preferably counted by weight percentage, glycerol 10%～25%, and ethanol 10%～25%, boric acid 0.5%～3%, surplus is a water.
As a specific embodiment, in the wherein said solvent, calculate 100 parts of glycerol, 100 parts of ethanol, 10 parts of boric acid, 325 parts in water by weight.
Another purpose of the present invention provides a kind of method for preparing above-mentioned described Imiquimod turbid liquor, it comprises the steps: the water-soluble one-tenth boric acid solution of (1) boric acid, after (2) imiquimod is used the glycerol moistening, adds boric acid solution, stir, add ethanol again and make the suspension solution that is creamy white.
The present invention also provides a kind of Imiquimod formulation, and it comprises above-mentioned described Imiquimod turbid liquor and acceptable accessories.Can be according to the needs of preparation, choose suitable, corresponding medicinal adjuvant, make needed pharmaceutical preparation.Concerning one of ordinary skill in the art, it belongs to general pharmaceutical technology.
As one of embodiment of above-mentioned described preparation, the present invention also provides a kind of concrete Imiquimod formulation, and it is a gel, comprises above-mentioned described Imiquimod turbid liquor, gel-type vehicle and pH regulator agent.
Wherein, above-mentioned described gel-type vehicle is preferably acrylic crosslinking polymer, and Acritamer 940 more preferably is to make aqueogel.Its consumption is suitable for coating to have suitable denseness and viscosity.Be generally 0.5%～2%, be preferably 1%.
Wherein, above-mentioned described pH regulator agent, the pH value that is used for regulating gel is to suitable acid-base value, between pH value 6～8, to be fit to application need.Described pH regulator agent can be pharmaceutically conventional acidity-basicity regulator, and the present invention preferably uses triethanolamine as the pH regulator agent.
The present invention also provides a kind of method for preparing above-mentioned described imiquimod gel, comprises wherein said Imiquimod turbid liquor is under agitation slowly joined in the gel-type vehicle, after stirring, adds the step of pH regulator agent to pH value 6～8.
Add meeting creating pockets of air in the gel-type vehicle whipping process at Imiquimod turbid liquor, can leave standstill about about 5 minutes, treat to continue again to stir after bubble is got rid of.Prepared finished product is semi-solid.Abundant mix homogeneously when Imiquimod turbid liquor mixes with gel-type vehicle.Gel finished product pH value is adjusted to 6～8.
As specific embodiment of the present invention, a kind of imiquimod gel is provided, wherein contain imiquimod 50 grams, boric acid 10 grams, glycerol 100 grams, dehydrated alcohol 100 grams, Acritamer 940 10 grams, triethanolamine 5 grams and distilled water 725 grams, make 1000 gram gels by the method that comprises the steps: (1) boric acid adds in the 325 gram distilled water makes dissolving obtain boric acid solution; (2) imiquimod glycerol moistening adds boric acid solution and dehydrated alcohol and makes it the suspension solution that is creamy white, and obtains Imiquimod turbid liquor; (3) Acritamer 940 adds 400 gram distilled water, treats that the complete filtered through gauze of swelling obtains translucent substrate; (4) Imiquimod turbid liquor is under agitation joined in the above-mentioned translucent substrate, stir evenly, under agitation drip ethanolamine, get the opaque gel of milky.
Gel is compared with emulsifiable paste to have with skin coupling effect splendidly, helps the treatment of disease sites; Good looking appearance, fine and smooth smooth, no greasy feeling, easy cleaning reduce the pollution to medicated clothing; Better biocompatibility is arranged, and viscosity is less and help medicine; The advantages such as normal function that energy absorptive tissue transudate does not hinder skin.Thereby more convenient clinical application, raising patient's compliance.
Imiquimod is white or off-white color crystallization or crystalline powder, odorless.In water, ether, chloroform, all do not dissolve, easily molten among the HCl, slightly soluble among the 0.1mol/L HCl (1g:250ml), soluble,very slightly in the methanol.The present invention is surprised to find, the mixed solvent that employing is made up of glycerol, ethanol, boric acid solution can obtain relatively stable and uniform Imiquimod turbid liquor, thereby realize the purpose of imiquimod development, more how may for the development of imiquimod novel formulation provides for other preparations such as gels.
Especially, many antiseptic may destroy gel.The present invention also is surprised to find that, the ethanol in the mixed solvent, or the effective antiseptic of imiquimod gel, and simultaneously, glycerol can also generate glyceroborate with boric acid except that can be used as wetting agent or wetting agent, and bactericidal effect is strengthened.Therefore, Imiquimod turbid liquor of the present invention and pharmaceutical preparation thereof, gel as described need not to add other antiseptic or antibacterial again, just has good anticorrosion or fungistatic effect.
Imiquimod turbid liquor of the present invention and imiquimod gel, preparation technology is simple to operation, and technology be easy to control, good reproducibility is suitable for industrialized great production.Prepared imiquimod gel smooth in appearance, even, fine and smooth is easy to coating.
The specific embodiment
Come further to set forth content of the present invention by the following examples.Described embodiment is in order to understand purport of the present invention better, rights protection scope of the present invention not to be constituted qualification.
Embodiment 1
Imiquimod is crossed 200 mesh sieves, gets imiquimod 50 grams, adds the glycerol moistening of 100 grams, mixing adds boric acid solution (10 gram boric acid are dissolved in the resulting solution of 325 gram water) again, and 100 gram dehydrated alcohol, stir evenly, the suspendible shape liquid that is creamy white promptly gets Imiquimod turbid liquor.
Embodiment 2
Get imiquimod 20 grams, be ground into fine powder, add 50 gram glycerol and carry out moistening and stirring and evenly mixing.Add 120 gram 3.5% boric acid solution and 40 grams, 95% ethanol again, stir evenly, obtain milky suspension solution, promptly.
Embodiment 3
Get 10 gram Acritamer 940s, add distilled water 400g, treat to use filtered through gauze after swelling fully, obtain translucent substrate.Embodiment 1 resulting Imiquimod turbid liquor is joined in the above-mentioned translucent substrate, and the limit edged stirs and makes it mix homogeneously, stirs evenly back Dropwise 5 gram triethanolamine, stirs while dripping, and the opaque gel that is creamy white promptly obtains the imiquimod gel.
The above-mentioned imiquimod gel that obtains, pH value is 6.89.Granularity 10-50 μ m, product appearance is smooth, and uniform and smooth is easy to coating.Room temperature was placed 30 days, and gel stability is good, and the adjuvant stable in properties with principal agent compatibility does not take place and changes.
Embodiment 4 (contrast test)
4a) prepare the imiquimod gel, wherein add 10 gram azones according to embodiment 3 same procedure.
4b) prepare the imiquimod gel, wherein add 10 gram tween 80s according to embodiment 3 same procedure.
The result shows: investigate from prepared sample appearance, after 4a and 4b added azone, tween, medicine was assembled, and naked eyes are as seen than large crumb.
According to above-mentioned preferred embodiment the present invention has been made detailed description.It should be noted that above embodiment is just to illustrating the present invention.Under the prerequisite that does not depart from spirit of the present invention and essence, those skilled in the art can design multiple alternative of the present invention and improvement project, and it all should be understood to be within protection scope of the present invention.
Claims (10)
1, a kind of Imiquimod turbid liquor comprises imiquimod and solvent, it is characterized in that the mixed solvent of described solvent for being made up of glycerol, ethanol, boric acid and water.
2, Imiquimod turbid liquor according to claim 1 in the wherein said solvent, is counted by weight percentage, glycerol 10%～25%, and ethanol 10%～25%, boric acid 0.5%～3%, surplus is a water.
3,, in the wherein said solvent, calculate 100 parts of glycerol, 100 parts of ethanol, 10 parts of boric acid, 325 parts in water by weight according to the described Imiquimod turbid liquor of claim 1-2.
4, a kind of method for preparing the described Imiquimod turbid liquor of claim 1-3, comprise the steps: the water-soluble one-tenth boric acid solution of (1) boric acid, after (2) imiquimod is used the glycerol moistening, add boric acid solution, stir, add ethanol again and make the suspension solution that is creamy white.
5, a kind of Imiquimod formulation, it comprises described Imiquimod turbid liquor of claim 1-3 and acceptable accessories.
6, Imiquimod formulation according to claim 5, it is a gel, comprises the described Imiquimod turbid liquor of claim 1-3, gel-type vehicle and pH regulator agent.
7, Imiquimod formulation according to claim 6, wherein said gel-type vehicle comprises acrylic crosslinking polymer, is preferably Acritamer 940.
8, according to the described Imiquimod formulation of claim 6-7, wherein said pH regulator agent is a triethanolamine.
9, a kind of method for preparing the described imiquimod gel of claim 6-8 comprises wherein said Imiquimod turbid liquor is under agitation slowly joined in the gel-type vehicle, after stirring, adds the step of pH regulator agent to pH value 6～8.
10, a kind of imiquimod gel, wherein contain imiquimod 50 grams, boric acid 10 grams, glycerol 100 grams, dehydrated alcohol 100 grams, Acritamer 940 10 grams, triethanolamine 5 grams and distilled water 725 grams, make 1000 gram gels by the method that comprises the steps: (1) boric acid adds in the 325 gram distilled water makes dissolving obtain boric acid solution; (2) imiquimod glycerol moistening adds boric acid solution and dehydrated alcohol and makes it the suspension solution that is creamy white, and obtains Imiquimod turbid liquor; (3) Acritamer 940 adds 400 gram distilled water, treats that the complete filtered through gauze of swelling obtains translucent substrate; (4) Imiquimod turbid liquor is under agitation joined in the above-mentioned translucent substrate, stir evenly, under agitation drip ethanolamine, get the opaque gel of milky.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101407862A CN100450484C (en) | 2006-10-11 | 2006-10-11 | Imiquimod turbid liquor and gelling agent thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101407862A CN100450484C (en) | 2006-10-11 | 2006-10-11 | Imiquimod turbid liquor and gelling agent thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1923170A true CN1923170A (en) | 2007-03-07 |
| CN100450484C CN100450484C (en) | 2009-01-14 |
Family
ID=37816114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101407862A Expired - Fee Related CN100450484C (en) | 2006-10-11 | 2006-10-11 | Imiquimod turbid liquor and gelling agent thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100450484C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103202803A (en) * | 2012-12-18 | 2013-07-17 | 苏州大学 | Imiquimod vesicle gel and preparation method for same |
| CN114010592A (en) * | 2021-11-05 | 2022-02-08 | 苏州百迈生物医药有限公司 | Imiquimod suspension preparation, and preparation method and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0023008D0 (en) * | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| CN1286529C (en) * | 2004-06-11 | 2006-11-29 | 华中科技大学 | Skin targeting medicinal composition and its preparation and use |
-
2006
- 2006-10-11 CN CNB2006101407862A patent/CN100450484C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103202803A (en) * | 2012-12-18 | 2013-07-17 | 苏州大学 | Imiquimod vesicle gel and preparation method for same |
| CN103202803B (en) * | 2012-12-18 | 2015-05-13 | 苏州大学 | Imiquimod vesicle gel and preparation method for same |
| CN114010592A (en) * | 2021-11-05 | 2022-02-08 | 苏州百迈生物医药有限公司 | Imiquimod suspension preparation, and preparation method and application thereof |
| CN114010592B (en) * | 2021-11-05 | 2024-02-06 | 苏州百迈生物医药有限公司 | Imiquimod suspension preparation capable of being injected in tumor or around tumor as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100450484C (en) | 2009-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3650776T2 (en) | Polysaccharide esters and their salts | |
| US9822243B2 (en) | Freeze-dried composition | |
| CN102871956B (en) | Propranolol hydrochloride gel for treating infant superficial hemangioma | |
| CN1814279A (en) | Regenerated human alkali fiber-cell growth factor gel former and preparing method | |
| KR20190021205A (en) | Nanofibrous mat containing ceramic particles with releasable dopant | |
| JP2006522822A (en) | Alcohol-free transdermal insulin composition and process and use thereof | |
| CN103565743A (en) | Tranexamic acid skin externally applied nano-preparation, as well as preparation method and use thereof | |
| CN102949709A (en) | External gel used for treating diabetic foot, and preparation method and application thereof | |
| CN101036695A (en) | Oil-in-water type nanometer emulsion of costus root oil and litsea cubeba oil and preparation method thereof | |
| CN106176758B (en) | A kind of externally-applied medicinal composition | |
| CN109820824A (en) | A kind of capsaicine liquid crystal nano-spray preparation and preparation method thereof for promoting skin wound healing | |
| CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| CN102379862A (en) | Spirosal-containing hydrophilic cataplasm | |
| CN1989956A (en) | Adapalene gel composition and its preparation | |
| CN112263544B (en) | Lidocaine hydrochloride gel and preparation method thereof | |
| CN109662942A (en) | A kind of antibacterial temperature sensitive type gel preparation and preparation method thereof | |
| CN100450484C (en) | Imiquimod turbid liquor and gelling agent thereof | |
| CN108670945A (en) | A kind of nanogel preparation and preparation method thereof with double slow releasing functions | |
| CN115554243B (en) | Minocycline foam for treating acne rosacea | |
| CN108743534B (en) | Tripterine or tripterine derivative vesicle and preparation method thereof | |
| CN111184683A (en) | Hydrogel capable of being used for synergistic transdermal drug delivery and preparation method and application thereof | |
| CN114748451B (en) | Timolol maleate external preparation and preparation method thereof | |
| CN108309930B (en) | Ofloxacin liquid crystal gel nanoparticle eye drops and preparation method thereof | |
| MXPA06014625A (en) | Binary thermo-gelling composition. | |
| CN106214624A (en) | For treating timolol maleate preparation and the application thereof of baby's Superficial hemangioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15 Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100080, room 1410, satellite building, No. 63, Zhichun Road, Beijing, Haidian District Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230320 Address after: 8639, Floor 6, Building 3, No. 3, Yongchang North Road, Daxing District, Beijing, 100176 Patentee after: Beijing Kexin Jurun Pharmaceutical Technology Co.,Ltd. Address before: 100083 room 15, 15 / F, block a, Tiangong building, 30 Xueyuan Road, Haidian District, Beijing Patentee before: COSCI MED-TECH Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090114 |